Back to Search
MARK RUBENSTEIN, M.D.
M.D.
Pain Medicine (Physical Medicine & Rehabilitation) Physician
NPI: 1598743437Individual
Specialties, Licenses & Credentials
Pain Medicine (Physical Medicine & Rehabilitation) PhysicianPrimary
Physical Medicine & Rehabilitation — Pain Medicine
Code: 2081P2900X
ME0067700(FL)
Research & Publications (20)
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
PMID 19533419·Med Oncol·2010
8-other
Regenerative patterning in Swarm Robots: mutual benefits of research in robotics and stem cell biology.
PMID 19557691·Int J Dev Biol·2009
7-preclinical
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
PMID 18686047·Med Oncol·2009
4-observational
Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease.
PMID 17879274·Inflamm Bowel Dis·2008
8-other
Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites?
PMID 18364249·Med Hypotheses·2008
7-preclinical
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
PMID 17972023·Med Oncol·2008
8-other
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17848743·Med Oncol·2007
4-observational
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
PMID 17917084·Med Oncol·2007
8-other
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
PMID 17541843·J Drug Target·2007
7-preclinical
Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus.
PMID 17402372·Lupus·2007
8-other
To what extent are the "sets" of biologic properties expressed by hypoxic cancer cells and by cancer "stem" cells equivalent, intersecting, disjoint or complementary? Some implications for the design of cancer therapies.
PMID 16934948·Med Hypotheses·2007
7-preclinical
Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
PMID 16870352·Med Hypotheses·2006
8-other
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
PMID 17136230·Methods Find Exp Clin Pharmacol·2006
8-other
Disparate forms of MK 886-induced programmed death in BCL-2 (+) blood and BCL-2 (-) solid cancer cells and a putative "nuclear" Ca2+ channel: "soil" trumps "seed"?
PMID 15607561·Med Hypotheses·2005
8-other
Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis.
PMID 16192687·J Biomed Biotechnol·2005
8-other
Potassium-titanyl-phosphate laser laparoscopic partial nephrectomy without hilar clamping in the survival calf model.
PMID 16094075·J Urol·2005
7-preclinical
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
PMID 16023790·Med Hypotheses·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4495 MILITARY TRAIL, SUITE 209
JUPITER, FL 33458 - Phone
- (561) 296-9991
Quick Facts
- NPI
- 1598743437
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile